K-CAB's U.S. Phase 3 Clinical Trial Results Expected in the Second Half
Reasons to Watch HK Inno.N in the Second Half of the Year
HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and promising U.S. clinical trial results.
On the 9th, the securities industry…